Acute leukemias of ambiguous lineage in adults: Molecular and clinical characterization

Annals of Hematology

Volumn 92, Issue 6, 2013, Pages 747-758

  Heesch, Sandra ^a   Neumann, Martin ^a   Schwartz, Stefan ^a   Bartram, Isabelle ^a   Schlee, Cornelia ^a   Burmeister, Thomas ^a   Hänel, Matthias ^b   Ganser, Arnold ^c   Heuser, Michael ^c   Wendtner, Clemens Martin ^d   Berdel, Wolfgang E ^e   Gökbuget, Nicola ^f   Hoelzer, Dieter ^f   Hofmann, Wolf Karsten ^g   Thiel, Eckhard ^a   Baldus, Claudia D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Klinikum Schwabing   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Acute undifferentiated leukemia; BAALC, IGFBP7; Biphentotypic acute leukemia; Flow cytometry; Molecular characteristics

Indexed keywords

BCR ABL PROTEIN; WT1 PROTEIN;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE UNDIFFERENTIATED LEUKEMIA; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BAALC GENE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; ERG GENE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; IGFBP7 GENE; LEUKEMIA REMISSION; LONG TERM SURVIVAL; LYMPHATIC LEUKEMIA; MALE; MN1 GENE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINEAGE; COMBINED MODALITY THERAPY; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA; LEUKEMIA, BIPHENOTYPIC, ACUTE; LYMPHOCYTES; MALE; MIDDLE AGED; MUTATION; MYELOID CELLS; NEOPLASM PROTEINS; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877786612     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1694-4     Document Type: Article

References (50)

1. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, Van't Veer MB (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783-1786
2. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, Van't Veer MB (1998) The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 92:596-599
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951. doi: 10.1182/blood-2009-03-209262
4. Borowitz MJ, Béné M-C, Harris NL, Porwit A, Matutes E (2009) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Volume 2, Chapter 7: 150 pp
5. Bene MC, Porwit A (2012) Acute leukemias of ambiguous lineage. Semin Diagn Pathol 29:12-18
6. Zhang Y, Wu D, Sun A, Qiu H, He G, Jin Z, Tang X, Miao M, Fu Z, Han Y (2011) Clinical characteristics, biological profile, and outcome of biphenotypic acute leukemia: a case series. Acta Haematol 125:210-218. doi: 10.1159/000322594
7. Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD (2011) Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 117. doi: 10.1182/blood-2010-10-314682
8. Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, Ramond S, Viguie F, Marie JP, Zittoun R (1998) Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol 100:147-155
9. Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven JG, Zomas A, Atra A, Catovsky D (1999) Outcome of biphenotypic acute leukemia. Haematologica 84:699-706
10. Rubio MT, Dhedin N, Boucheix C, Bourhis JH, Reman O, Boiron JM, Gallo JH, Lheritier V, Thomas X, Fiere D, Vernant JP (2003) Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome. Br J Haematol 123:842-849
11. Tiribelli M, Damiani D, Masolini P, Candoni A, Calistri E, Fanin R (2004) Biological and clinical features of T-biphenotypic acute leukaemia: report from a single centre. Br J Haematol 125:814-815
12. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F (2007) Biphenotypic acute leukaemia: a case series. Br J Haematol 138:213-216
13. Xu XQ, Wang JM, Lu SQ, Chen L, Yang JM, Zhang WP, Song XM, Hou J, Ni X, Qiu HY (2009) Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. Haematologica 94:919-927. doi: 10.3324/haematol.2008.003202
14. Zheng C, Wu J, Liu X, Ding K, Cai X, Zhu W (2009) What is the optimal treatment for biphenotypic acute leukemia? Haematologica 94:1778-1780. doi: 10.3324/haematol.2009.014829
15. Owaidah TM, Al BA, Iqbal MA, Elkum N, Roberts GT (2006) Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 20:620-626
16. Lee JH, Min YH, Chung CW, Kim BK, Yoon HJ, Jo DY, Shin HJ, Bang SM, Won JH, Zang DY, Kim HJ, Chi HS, Lee KH, Cheong JW, Kim JS, Kim SH, Park S, Park SY, Chung JS, Lee JH, Park CJ (2008) Prognostic implications of the immunophenotype in biphenotypic acute leukemia. Leuk Lymphoma 49:700-709. doi: 10.1080/10428190701843247
17. Rubnitz JE, Onciu M, Pounds S, Shurtleff S, Cao X, Raimondi SC, Behm FG, Campana D, Razzouk BI, Ribeiro RC, Downing JR, Pui CH (2009) Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood 113:5083-5089. doi: 10.1182/blood-2008-10-187351
18. Brito-Babapulle F, Pullon H, Layton DM, Etches A, Huxtable A, Mangi M, Bellingham AJ, Mufti GJ (1990) Clinicopathological features of acute undifferentiated leukaemia with a stem cell phenotype. Br J Haematol 76:210-214
19. Bassan R, Biondi A, Benvestito S, Tini ML, Abbate M, Viero P, Barbui T, Rambaldi A (1992) Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer 69:396-404
20. Cuneo A, Ferrant A, Michaux JL, Bosly A, Chatelain B, Stul M, Dal CP, Dierlamm J, Cassiman JJ, Hossfeld DK, Castoldi G, Van den Berghe H (1996) Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine cases. Cancer Genet Cytogenet 92:31-36
21. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD (2010) Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 95:942-949. doi: 10.3324/haematol.2009.016386
22. Heesch S, Schlee C, Neumann M, Stroux A, Kuhnl A, Schwartz S, Haferlach T, Goekbuget N, Hoelzer D, Thiel E, Hofmann WK, Baldus CD (2010) BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia 24:1429-1436. doi: 10.1038/leu.2010.130
23. Kuhnl A, Gokbuget N, Stroux A, Burmeister T, Neumann M, Heesch S, Haferlach T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD (2010) High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737-3744. doi: 10.1182/blood-2009-09-241943
24. Kuhnl A, Kaiser M, Neumann M, Fransecky L, Heesch S, Radmacher M, Marcucci G, Bloomfield CD, Hofmann WK, Thiel E, Baldus CD (2011) High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res 35:1585-1590. doi: 10.1016/j.leukres.2011.08.006
25. Schwartz S, Rieder H, Schlager B, Burmeister T, Fischer L, Thiel E (2003) Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/ CD65s(+)/CD15(+) B-cell phenotype. Leukemia 17:1589-1595
26. Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK (2007) Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739-3745. doi: 10.1200/JCO.2007.11.5253
27. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B, Ganser A (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898-3905. doi: 10.1182/blood-2006-04-014845
28. Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, Schneider B, Raff T, Reinhardt R, Gokbuget N, Hoelzer D, Thiel E, Marschalek R (2009) The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood 113:4011-4015
29. Burmeister T, Reinhardt R (2008) A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 32:579-585
30. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111:5371-5379
31. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242. doi: 10.1200/JCO.2005.03.6137
32. Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24:4714-4720. doi: 10.1200/JCO.2006.06.1580
33. Grosveld GC (2007) MN1, a novel player in human AML. Blood Cells Mol Dis 39:336-339
34. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E (1995) Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060-1067
35. Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, Schnittger S, Haferlach T (2011) Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer. doi: 10.1002/gcc.20950
36. LeMaistre A, Childs CC, Hirsch-Ginsberg C, Reuben J, Cork A, Trujillo JM, Andersson B, McCredie KB, Freireich E, Stass SA (1988) Heterogeneity in acute undifferentiated leukemia. Hematol Pathol 2:79-90
37. Von LM, Breems D, Van BS, Adriaansen H, Grosveld G (1992) Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 5:227-234
38. Kim J, Lee SG, Song J, Kim SJ, Rha SY, Lee KA, Park TS, Choi JR (2010) Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. Cancer Genet Cytogenet 201:73-80. doi: 10.1016/j.cancergencyto.2010.05.010
39. Carbonell F, Swansbury J, Min T, Matutes E, Farahat N, Buccheri V, Morilla R, Secker-Walker L, Catovsky D (1996) Cytogenetic findings in acute biphenotypic leukaemia. Leukemia 10:1283-1287
40. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830
41. Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel E (2008) Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood 112:918-919. doi: 10.1182/blood-2008-04-149286
42. Matsumoto Y, Taki T, Fujimoto Y, Taniguchi K, Shimizu D, Shimura K, Uchiyama H, Kuroda J, Nomura K, Inaba T, Shimazaki C, Horiike S, Taniwaki M (2009) Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution. Int J Hematol 89:352-358. doi: 10.1007/s12185-009-0268-7
43. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335
44. Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, Benlasfer O, Farhadi-Sartangi N, Thibaut J, Burmeister T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD (2012) Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2:e55
45. King-Underwood L, Pritchard-Jones K (1998) Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91:2961-2968
46. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, Cavenagh J, Bonnet D, Young BD, Lister TA, Fitzgibbon J (2007) Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21:550-551. doi: 10.1038/sj.leu.2404514
47. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-4602. doi: 10.1200/JCO.2007.15.2058
48. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister TA, Fitzgibbon J (2008) Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429-5435. doi: 10.1200/JCO.2008.16.0333
49. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA (2009) WT1 mutations in T-ALL. Blood 114:1038-1045. doi: 10.1182/blood-2008-12-192039
50. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113:6541-6548. doi: 10.1182/blood-2009-02-202598